Clinically Significant Effect Sizes for Survival and Response Endpoints Using the 1/2 Standard Deviation Rule.
- Citation:
- Qual Life Res vol 19 (40) abstr 1772
- Meeting Instance:
- ISOQOL 2010
- Year:
- 2010
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- Yes
- Biospecimen:
- No
- SDC:
- Yes
- Parents:
- None
- Children:
- 2235
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- J. A. Sloan P. J. Novotny D. J. Sargent P. Decker R. Qin
- Networks:
- Study
- NCCTG-N9741
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: